Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE: Adoptive Cell Therapy (NK or Memory T Cells) for COVID-19
NCT04578210Phase 2Completed
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Natural Killer Cells in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Hospital La Paz Institute for Health Research. Primary endpoints: Occurrence of Dose-Limiting Toxicities at 21 days and Proportion of patients with normalization of fever, oxygen saturation and lymphopenia recovery at 14 days. Started Sep 2020; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04578210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578210.